Cellosaurus logo
expasy logo

Cellosaurus H9 (CVCL_1240)

[Text version]
Cell line name H9
Synonyms HT clone H9; HT(H9); H 9; H-9
Accession CVCL_1240
Resource Identification Initiative To cite this cell line use: H9 (RRID:CVCL_1240)
Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Population: Caucasian.
Virology: Permissive for HIV-1 replication. Is accordingly used to isolate and propagate HIV-1 from the blood of patients with AIDS.
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Deep exome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Anecdotal: For a number of years it was not known that H9 used by Gallo's lab to isolate HIV-1 (HTLV-III) was in fact a clone of Hut 78 from Minna's lab (PubMed=2567177). This created a controversy between the labs of Minna and Gallo (PubMed=2193399).
Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
Cell type: T-cell; CL=CL_0000084.
Sequence variations
  • Gene deletion; HGNC; 7208; MPDZ; Zygosity=Homozygous (from parent cell line).
  • Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (Cosmic-CLP=907043; DepMap=ACH-002240).
  • Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Homozygous (Cosmic-CLP=907043; DepMap=ACH-002240).
HLA typing Source: PubMed=7707540
Class II
HLA-DRDRB1*04:01
Genome ancestry Source: PubMed=30894373

Origin% genome
African4.91
Native American1.41
East Asian, North5.59
East Asian, South0
South Asian0
European, North61.37
European, South26.72
Disease Sezary syndrome (NCIt: C3366)
Sezary syndrome (ORDO: Orphanet_3162)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_0337 (HuT 78)
Children:
CVCL_X680 (H9/HIV-2MVP-11971)CVCL_X681 (H9/HIV-2MVP-15132)CVCL_3514 (H9/HTLV-IIIB)
CVCL_X621 (H9/HTLV-IIICC)CVCL_X620 (H9/HTLV-IIIMN)CVCL_X619 (H9/HTLV-IIIRF)
CVCL_E3D8 (H9/R7hyg)CVCL_E3D9 (H9/R7neo)CVCL_X610 (H9/SIVmac186)
CVCL_D536 (H938)CVCL_U264 (RH9)
Sex of cell Male
Age at sampling 53Y
Category Cancer cell line
STR profile Source(s): ATCC=HTB-176; CLS=300460; Cosmic-CLP=907043; ECACC=85050301; KCLB=30176

Markers:
AmelogeninX,Y
CSF1PO11
D2S133820,25
D3S135815,16
D5S81811
D6S104312
D7S8208,11
D8S117912,14
D12S39118,23
D13S3178,12
D16S53911,12
D18S5118
D19S43314
D21S1130
FGA21,25
Penta D9
Penta E13,15
TH018,9
TPOX8,9
vWA14,15

Run an STR similarity search on this cell line
Web pages http://www.nibsc.org/Default.aspx?pageid=597&id=0001&theme=default
http://www.bmj.com/rapid-response/2011/10/30/cell-lines-hut102-and-hut78
Publications

PubMed=6151082; DOI=10.1016/S0140-6736(84)91666-0
Popovic M., Read-Connole E.L., Gallo R.C.
T4 positive human neoplastic cell lines susceptible to and permissive for HTLV-III.
Lancet 324:1472-1473(1984)

PubMed=2567177; DOI=10.1089/aid.1989.5.253
Mann D.L., O'Brien S.J., Gilbert D.A., Reid Y.A., Popovic M., Read-Connole E.L., Gallo R.C., Gazdar A.F.
Origin of the HIV-susceptible human CD4+ cell line H9.
AIDS Res. Hum. Retroviruses 5:253-255(1989)

PubMed=2193399; DOI=10.1126/science.2193399
Rubinstein E.
The untold story of HUT78.
Science 248:1499-1507(1990)

PubMed=1460674; DOI=10.1093/jnci/84.24.1922
Chen T.-R.
Karyotypic derivation of H9 cell line expressing human immunodeficiency virus susceptibility.
J. Natl. Cancer Inst. 84:1922-1926(1992)

PubMed=8320746; DOI=10.1093/jnci/85.14.1168
Bunn P.A. Jr., Whang-Peng J., Gazdar A.F., Minna J.D., Carney D.N.
Karyotypic derivation of H9 cell line.
J. Natl. Cancer Inst. 85:1168-1169(1993)

PubMed=8127147
Heyman M., Grander D., Brondum-Nielsen K., Cederblad B., Liu Y., Xu B., Einhorn S.
Interferon system defects in malignant T-cells.
Leukemia 8:425-434(1994)

PubMed=7707540; DOI=10.1128/JVI.69.5.3117-3124.1995; PMCID=PMC189013
Arthur L.O., Bess J.W. Jr., Urban R.G., Strominger J.L., Morton W.R., Mann D.L., Henderson L.E., Benveniste R.E.
Macaques immunized with HLA-DR are protected from challenge with simian immunodeficiency virus.
J. Virol. 69:3117-3124(1995)

PubMed=8641406; DOI=10.1111/j.1600-0609.1996.tb00721.x
Borgonovo-Brandter L., Heyman M., Rasool O., Liu Y., Grander D., Einhorn S.
p16INK4/p15INK4B gene inactivation is a frequent event in malignant T-cell lines.
Eur. J. Haematol. 56:313-318(1996)

PubMed=17170727; DOI=10.1038/sj.leu.2404486
Sandberg Y., Verhaaf B., van Gastel-Mol E.J., Wolvers-Tettero I.L.M., De Vos J., MacLeod R.A.F., Noordzij J.G., Dik W.A., van Dongen J.J.M., Langerak A.W.
Human T-cell lines with well-defined T-cell receptor gene rearrangements as controls for the BIOMED-2 multiplex polymerase chain reaction tubes.
Leukemia 21:230-237(2007)

PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113
Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

Cross-references
Cell line collections (Providers) ATCC; HTB-176
BEI_Resources; ARP-87
CCTCC; GDC0031
CLS; 300460
ECACC; 85050301
ICLC; HTL05006
IZSLER; BS TCL 19 - Discontinued
KCB; KCB 200418YJ
KCLB; 30176
Cell line databases/resources CLO; CLO_0003581
CLO; CLO_0003612
CLDB; cl1556
CLDB; cl1557
CLDB; cl7167
cancercelllines; CVCL_1240
CCRID; 4201MOU-CCTCC00031
Cell_Model_Passport; SIDM01251
Cosmic-CLP; 907043
DepMap; ACH-002240
LINCS_LDP; LCL-1144
Lonza; 910
TOKU-E; 3613
Anatomy/cell type resources BTO; BTO:0001944
Biological sample resources BioSample; SAMN03472731
Chemistry resources ChEMBL-Cells; CHEMBL3308402
ChEMBL-Targets; CHEMBL614806
GDSC; 907043
PharmacoDB; H9_439_2019
PubChem_Cell_line; CVCL_1240
Encyclopedic resources Wikidata; Q54872230
Experimental variables resources EFO; EFO_0003045
Gene expression databases ArrayExpress; E-MTAB-783
ArrayExpress; E-MTAB-3610
GEO; GSM1669836
Polymorphism and mutation databases Cosmic; 687842
Cosmic; 907043
Cosmic; 933542
Cosmic; 2301568
Cosmic; 2668295
IARC_TP53; 21356
Proteomic databases PRIDE; PXD030304
Sequence databases EGA; EGAS00001000978
Entry history
Entry creation04-Apr-2012
Last entry update10-Sep-2024
Version number39